Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Join SI Premium – FREE
Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- BancFirst Corp. (BANF) Tops Q3 EPS by 3c
- Axis Capital Limited Starts Bagmane Prime Office REIT (BAGMANE:IN) at Add (2)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
